Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flumazenil

FDA-approved product (injectable, injection), marketed as Flumazenil, Romazicon.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Flumazenil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Flumazenil. Its therapeutic class is shown instead.

WHO therapeutic group
Antidotes
FDA pharmacologic class
Benzodiazepine Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flumazenil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flumazenil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prometa Protocol for Alcohol Dependence

    NCT00262639 · start 2005-12

    Registered record
    Registry ID
    NCT00262639
    Conditions
    Alcohol Dependence
    Interventions
    Flumazenil and Gabapentin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    InterventionFlumazenil and Gabapentin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome

    NCT00034398 · start 2002-04-24

    Registered record
    Registry ID
    NCT00034398
    Conditions
    Tourette Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-04-24
    Completion
    2010-03-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourette Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Effects of Flumazenil on Brain Excitability

    NCT00015678 · start 2001-04

    Registered record
    Registry ID
    NCT00015678
    Conditions
    Stroke; Healthy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-04
    Completion
    2002-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Healthy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Rapid Benzodiazepine Detoxification Using Flumazenil - 1

    NCT00000246 · start 1993-01

    Registered record
    Registry ID
    NCT00000246
    Conditions
    Substance-Related Disorders
    Interventions
    Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1993-01
    Completion
    1994-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubstance-Related Disorders
    InterventionFlumazenil
    PhasePhase 2
    Registry statusCompleted

  • Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

    NCT00781482

    Registered record
    Registry ID
    NCT00781482
    Conditions
    Healthy
    Interventions
    eszopiclone, zolpidem, placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioneszopiclone, zolpidem, placebo
    PhasePhase 4
    Registry statusWithdrawn